Stock PTPI PETROS PHARMACEUTICALS
Add to a list
To use this feature you must be a member
Log inSign up

News Petros Pharmaceuticals

Equities

PTPI

US71678J2096

Delayed Nasdaq
Other stock markets
 01:25:48 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.6449 USD +0.78% Intraday chart for Petros Pharmaceuticals -3.76% -54.26%
Apr. 23 Petros, Lemonaid Health Collaborate to Expand Stendra Availability MT
Apr. 23 Petros Pharmaceuticals, Inc. Expands Online Distribution for Prescription STENDRA Through New Agreement with Lemonaid Health CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Petros Pharmaceuticals announces online distribution for lead ED product with Lemonaid Health
AQ
Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA through New Agreement with Lemonaid Health
AQ
Petros, Lemonaid Health Collaborate to Expand Stendra Availability
MT
Petros Pharmaceuticals, Inc. Expands Online Distribution for Prescription STENDRA Through New Agreement with Lemonaid Health
CI
Petros Gets 'Positive' FDA Response Over Technology Component in Stendra OTC Process
MT
Petros Pharmaceuticals Receives Positive Response from Fda Following Recent Demonstration of Technology Component in Pursuit of Otc Status for Stendra(R)
CI
Petros Pharmaceuticals, Inc. Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA as it Pursues OTC Status
CI
Petros Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
BestGrowthStocks.Com Issues Comprehensive Analysis of Petros Pharmaceuticals Inc
AQ
Petros Pharmaceuticals Enters into Ai Licensing Agreement with Leading Multi-Billion-Dollar Software Provider
CI
Thinking about buying stock in Helius Medical Technologies, Peraso, GDS Holdings, Everbridge, or Petros Pharmaceuticals?
PR
Top Premarket Gainers
MT
Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA Rx-to-OTC Switch
AQ
Petros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA Rx-to-OTC Switch
AQ
Petros Pharmaceuticals, Inc. Announces Successful Completion of the Initial Cohort of A Phase 2 Equivalent Self-Selection Study
CI
Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA the First Erectile Dysfunction Medication to Achieve OTC Status
AQ
Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor's OTC Switch Technology Provider
AQ
Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) the First Erectile Dysfunction Medication to Achieve OTC Status
CI
Maxim Initiates Petros Pharma at Buy Rating With $4 Price Target
MT
Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug Crestor's (Rosuvastatin) OTC Switch Technology Provider
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PTPI Stock
  4. News Petros Pharmaceuticals